MODULE 2 - ANSWER
DNA damaging drugs (2) - ANSWER Cyclophosphamide (DNA alkylating agent)
Cisplatin
Topoisomerase II drugs (2) - ANSWER Doxorubicin, Etoposide
Microtubule drugs (2) - ANSWER Vincristine
Paclitaxel
Antimetabolites (3) - ANSWER Methotrexate5-Fluorouracil (5-FU)Cytosine
arabinoside (Ara C)
Protein tyrosine kinase inhibitors (1) - ANSWER Imatinib
Cyclophosphamide mechanism - ANSWER Alkalating agent; DNA cross links
Haemorrhagic cystitis, Myelosuppression, and secondary malignancies
Cisplatin Mechanism - ANSWER DNA cross-link
Neuro and renal toxicity
Bleomycin Mechanism - ANSWER Free radicals --> DNA breaks
Pulmonary fibrosis
Topotecan Mechanism - ANSWER Topoisomerase I inhibitor
Myelosuppression
Doxorubicin Mechanism - ANSWER Topoisomerase inhibitor II
Myelosuppression and Cardiotoxicity
Etoposide Mechanism - ANSWER Topoisomerase inhibitor II
Myelosuppression
Paclitaxel - ANSWER Microtubule stabilization
Neurotoxicity, myelosuppression
Vincristine Mechanism - ANSWER Disruption of microtubules
Neurotoxicity
Methotrexate Mechanism - ANSWER Folate synthesis inhibitor (DHFR)
, Myelosuppression and Mucositis
F-Fluorouracil Mechanism - ANSWER Folate synthesis inhibitor (TS)
Myelosuppression and Mucositis
Cytarabine Mechanism - ANSWER Inhibit DNA elongations
Myelosuppression
MODULE 3 - ANSWER Targeted Therapy
EGFR Antibodies (6) - ANSWER Cetuximab
Erlotinib/Gefitinib
Gefitinib
Osimertinib
Trastuzumab
Lapatinib
Platelet Derived Growth Factor Receptor - PDGFR - ANSWER Oluratumab
Imatinib
SERMS(2) - ANSWER Tamoxifen
Raloxifene
SERDS (1) - ANSWER Fulvestrant
AIs (1) - ANSWER Anastrozole
Antiandrogens (1) - ANSWER Enzalutamide
Ionizing Radiation (6) - ANSWER Ionizing Radiation
Linear Energy Transfer (LET)
External Beam Radiation
Internal Radiation (Brachytherapy)
Radiosurgery
Cetuximab - ANSWER EGFR treatment binds extracellular domain III
- Blocks EGFR binding
- Induces antibody-dependent cell-mediated cytotoxicity
- ADCC
Erlotinib/Gefitinib - ANSWER EGFR treatment Inhibit ATP binding
- Prevents kinase activity
- Competitive inhibitor of ATP binding
Osimertinib - ANSWER EGFR treatment Inhibits ATP binding
- Prevents kinase activity
- Competitive inhibitor of ATP binding
DNA damaging drugs (2) - ANSWER Cyclophosphamide (DNA alkylating agent)
Cisplatin
Topoisomerase II drugs (2) - ANSWER Doxorubicin, Etoposide
Microtubule drugs (2) - ANSWER Vincristine
Paclitaxel
Antimetabolites (3) - ANSWER Methotrexate5-Fluorouracil (5-FU)Cytosine
arabinoside (Ara C)
Protein tyrosine kinase inhibitors (1) - ANSWER Imatinib
Cyclophosphamide mechanism - ANSWER Alkalating agent; DNA cross links
Haemorrhagic cystitis, Myelosuppression, and secondary malignancies
Cisplatin Mechanism - ANSWER DNA cross-link
Neuro and renal toxicity
Bleomycin Mechanism - ANSWER Free radicals --> DNA breaks
Pulmonary fibrosis
Topotecan Mechanism - ANSWER Topoisomerase I inhibitor
Myelosuppression
Doxorubicin Mechanism - ANSWER Topoisomerase inhibitor II
Myelosuppression and Cardiotoxicity
Etoposide Mechanism - ANSWER Topoisomerase inhibitor II
Myelosuppression
Paclitaxel - ANSWER Microtubule stabilization
Neurotoxicity, myelosuppression
Vincristine Mechanism - ANSWER Disruption of microtubules
Neurotoxicity
Methotrexate Mechanism - ANSWER Folate synthesis inhibitor (DHFR)
, Myelosuppression and Mucositis
F-Fluorouracil Mechanism - ANSWER Folate synthesis inhibitor (TS)
Myelosuppression and Mucositis
Cytarabine Mechanism - ANSWER Inhibit DNA elongations
Myelosuppression
MODULE 3 - ANSWER Targeted Therapy
EGFR Antibodies (6) - ANSWER Cetuximab
Erlotinib/Gefitinib
Gefitinib
Osimertinib
Trastuzumab
Lapatinib
Platelet Derived Growth Factor Receptor - PDGFR - ANSWER Oluratumab
Imatinib
SERMS(2) - ANSWER Tamoxifen
Raloxifene
SERDS (1) - ANSWER Fulvestrant
AIs (1) - ANSWER Anastrozole
Antiandrogens (1) - ANSWER Enzalutamide
Ionizing Radiation (6) - ANSWER Ionizing Radiation
Linear Energy Transfer (LET)
External Beam Radiation
Internal Radiation (Brachytherapy)
Radiosurgery
Cetuximab - ANSWER EGFR treatment binds extracellular domain III
- Blocks EGFR binding
- Induces antibody-dependent cell-mediated cytotoxicity
- ADCC
Erlotinib/Gefitinib - ANSWER EGFR treatment Inhibit ATP binding
- Prevents kinase activity
- Competitive inhibitor of ATP binding
Osimertinib - ANSWER EGFR treatment Inhibits ATP binding
- Prevents kinase activity
- Competitive inhibitor of ATP binding
